The US healthcare system is shifting away from volume-driven visits and tests, and toward value-based care, also known as measurement-based care. As of 2022, about 60% of healthcare payments in the US are tied to value and quality – a number likely higher today.
Reimbursement is tied to improved patient outcomes rather than the volume of services rendered as a strategy to reform the quality of healthcare and cut down on unnecessary costs.
For large healthcare organizations in ADHD, this presents both a challenge and an opportunity, where subjective evaluations and inconsistent treatment monitoring can largely get in the way of progress.
Integrating QbCheck into clinical workflows offers a strategic advantage.
The argument for objective measurement in ADHD care
Healthcare organizations like yours need to accurately measure quality and cost of care to thrive in a value-based care environment. You need a clear understanding of the costs associated with diagnosing and treating ADHD.
These costs can be high, or difficult to evaluate, where subjective ADHD measures are relied on. Subjective tests can lead to inconsistencies in diagnosis and treatment monitoring as well as lengthy and inefficient care pathways with vary per patient. Without data-driven clinical decision making, quality care can be low and costs high.
Positioning QbCheck as a strategic asset for your organization
Instead, invest in objective ADHD testing technology like QbCheck which provides clear and objective data on symptoms – allowing you to standardize and streamline your care pathway across your clinics. You can reduce time-to-diagnosis with a NICE recommended technology, providing your patients with timely care across your organization, regardless of where they are.
QbCheck quantifies core ADHD symptoms. You can make evidence-based decisions from a structured evaluation pathway, enhancing the precision of care.
You can provide payors with objective data that aligns with reimbursement criteria focused on patient outcomes. This integration allows providers to track treatment efficacy over time, ensuring that interventions are working as intended, positioning you favorably with payors prioritizing value over volume.
Enhancing treatment response evaluation
Under value-based care models, it’s more important than ever that large healthcare organizations adopt solutions that provide quantifiable data on patient progress when evaluating treatment efficacy.
Improve patient outcomes with QbCheck
We assessed the performance of remote testing with 6,159 patients. It was found that:
- 95% all patients reported that the instructions were easy to follow
- 94% of patients had an appropriate home test-environment.
QbCheck facilitates this by allowing direct comparisons across symptom severity in retest reports, enabling you to adjust treatment promptly. Research reported capturing up to 50% more patients responding to treatment compared to subjective measures alone in which approximately 36% showed treatment effects on the ASRS, providing evidence of treatment efficacy.
The quicker you can optimize your patient’s medication, the fewer appointments they need, and the faster you can improve their quality of life.
Improved patient experience and psychoeducation
Reports illustrating the objective data act as an anchor of communication between you and your patients. Research has reported that patients and family members enjoy the reports and having the information explained to them because they understand their symptoms better than they would when only subjective evaluations are used.
According to the landmark AQUA study:
- 94% of clinicians reported a greater understanding of patients’ symptoms
- 85% of families said the test is really helpful
- 153 days’ time reduction from assessments to diagnosis
- 20% of clinical workforce time freed
This fosters greater engagement in treatment plans and subsequently their health outcomes.
Economic benefits of improved ADHD management
Effective ADHD treatment not only enhances patient well-being but also reduces healthcare costs. In the UK, the integration of our technology into 15 health innovation networks across England saved the NHS £10 million and was subsequently used in 69 trusts across 150 sites.
Similar savings are achievable in the US, where ADHD misdiagnoses and treatment inefficiencies contribute to rising healthcare costs. By reducing unnecessary visits and optimizing treatment strategies, large healthcare organizations can see measurable financial benefits.
Objective testing technology can lead to more accurate diagnoses and tailored treatments, potentially decreasing unnecessary healthcare utilization and associated costs for patients and practices.